Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 4
1991 1
1995 5
1996 1
2000 1
2001 1
2002 2
2003 2
2004 2
2005 1
2006 3
2007 1
2008 5
2009 3
2010 2
2011 1
2013 10
2014 5
2015 13
2016 8
2017 11
2018 6
2019 11
2020 15
2021 28
2022 16
2023 18
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Results by year

Filters applied: . Clear all
Page 1
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
Kambhampati S, Saumoy M, Schneider Y, Pak S, Budde LE, Mei MG, Siddiqi T, Popplewell LL, Wen YP, Zain J, Forman SJ, Kwak LW, Rosen ST, Danilov AV, Herrera AF, Thiruvengadam NR. Kambhampati S, et al. Among authors: danilov av. Blood. 2022 Dec 22;140(25):2697-2708. doi: 10.1182/blood.2022016624. Blood. 2022. PMID: 35700381 Free PMC article.
Immunity in CLL: corrupt at inception?
Danilov AV. Danilov AV. Blood. 2022 Apr 7;139(14):2104-2105. doi: 10.1182/blood.2022015413. Blood. 2022. PMID: 35389445 Free article. No abstract available.
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML Cells.
Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D'Alessandro A, Culp-Hill R, d'Almeida A, Joshi SK, Rosenberg M, Tognon CE, Danilov AV, Druker BJ, Chang BH, McWeeney SK, Tyner JW. Nechiporuk T, et al. Among authors: danilov av. Cancer Discov. 2019 Jul;9(7):910-925. doi: 10.1158/2159-8290.CD-19-0125. Epub 2019 May 2. Cancer Discov. 2019. PMID: 31048320 Free PMC article.
Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
Wang X, Chen C, Vuong D, Rodriguez-Rodriguez S, Lam V, Roleder C, Wang JH, Kambhampati S, Berger A, Pennock N, Torka P, Hernandez-Ilizaliturri F, Siddiqi T, Wang L, Xia Z, Danilov AV. Wang X, et al. Among authors: danilov av. Leukemia. 2023 Jun;37(6):1324-1335. doi: 10.1038/s41375-023-01889-x. Epub 2023 Apr 8. Leukemia. 2023. PMID: 37031300 Free PMC article.
METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL.
Wu Y, Jin M, Fernandez M, Hart KL, Liao A, Ge X, Fernandes SM, McDonald T, Chen Z, Röth D, Ghoda LY, Marcucci G, Kalkum M, Pillai RK, Danilov AV, Li JJ, Chen J, Brown JR, Rosen ST, Siddiqi T, Wang L. Wu Y, et al. Among authors: danilov av. Blood Cancer Discov. 2023 May 1;4(3):228-245. doi: 10.1158/2643-3230.BCD-22-0156. Blood Cancer Discov. 2023. PMID: 37067905 Free PMC article.
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.
Phillips TJ, Bond D, Takiar R, Kump K, Kandarpa M, Boonstra P, Mayer TL, Nachar V, Wilcox RA, Carty SA, Karimi YH, Nikolovska-Coleska Z, Kaminski MS, Herrera AF, Maddocks K, Popplewell L, Danilov AV. Phillips TJ, et al. Among authors: danilov av. Blood Adv. 2023 Aug 22;7(16):4518-4527. doi: 10.1182/bloodadvances.2023009992. Blood Adv. 2023. PMID: 37013954 Free PMC article.
159 results